High response rate to PD-1 blockade in desmoplastic melanomas
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Desmoplastic melanoma is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, and is highly associated with ultraviolet light-induced DNA damage. We analysed sixty patients with advanced desmoplastic melanoma who had been treated with antibodies to block programmed cell death 1 (PD-1) or PD-1 ligand (PD-L1). Objective tumour responses were observed in forty-two of the sixty patients (70%; 95% confidence interval 57-81%), including nineteen patients (32%) with a complete response. Whole-exome sequencing revealed a high mutational load and frequent NF1 mutations (fourteen out of seventeen cases) in these tumours. Immunohistochemistry analysis from nineteen desmoplastic melanomas and thirteen non-desmoplastic melanomas revealed a higher percentage of PD-L1-positive cells in the tumour parenchyma in desmoplastic melanomas (P = 0.04); these cells were highly associated with increased CD8 density and PD-L1 expression in the tumour invasive margin. Therefore, patients with advanced desmoplastic melanoma derive substantial clinical benefit from PD-1 or PD-L1 immune checkpoint blockade therapy, even though desmoplastic melanoma is defined by its dense desmoplastic fibrous stroma. The benefit is likely to result from the high mutational burden and a frequent pre-existing adaptive immune response limited by PD-L1 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Neither anti-VEGF therapy nor ICB seem to be effective in highly desmoplastic tumours, such as pancreatic ductal adenocarcinoma, breast cancer, and cholangiocarcinoma7,110 — with the notable exception of desmoplastic melanomas, which have been shown to respond to ICB111.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“26 We noted five different patterns of CD8+ cell infiltration and PD-L1 expression in the invasive margin and tumour parenchyma, with most patients responding to therapy having one of the three patterns characterized by high CD8+ T cells (12 out of 14 with DM and six out of seven with non-DM,…”
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Whole exome sequencing from 17 cases in our DM cohort revealed greater than 82% C>T transitions as part of a strong signature of ultraviolet light induced DNA damage that is common to cutaneous melanoma 1,9 (Extended Data Figure 2a–b).”
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“Consistent with our previous observations 18 , the strongest correlation with clinical benefit (defined as having a complete or partial response, or prolonged stable disease for >12 months) was baseline density of CD8+ T cells in the invasive margin in non-DM melanoma (p=0.002, Extended Data Figure…”
InfluentialSelf-citationRittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 1×
“3,6 We did not find any genes mutated more frequently in patients with DM with or without response to therapy (Extended Data Figure 4a), including when doing specific analyses for potential detrimental mutations in the interferon receptor pathway or B2M that may result in innate or acquired…”
Self-citationPD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560 · cited 1×
“21,28 Our data suggests that DM, and probably the non-DM NF-1 subtype arising from sun-exposed areas, have a high response rate to PD-1 blockade therapy due to having a more dynamic pre-existing adaptive immune response process.”
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Self-citationSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Self-citationMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 1×
“14,17 We evaluated whether the presence of CD8+ T cells and PD-L1 in DM was associated with response to anti-PD1/L1 therapy 18,19 using 19 available pre-treatment DM tumour biopsies compared to 13 non-DM samples (seven with a complete or partial response, six with progressive disease) using digital…”
Self-citationGenomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151 · cited 2×
“13 Our DM series had similar mutational load to NF-1 subtype cases (regardless of histological classification) in a combined series from two reports of patients with anti-PD-1 treated advanced melanoma 14,15 and in TCGA data.”
Self-citationGenomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · cited 1×
“…sum p = 0.87, Figure 2b), a finding which is also true of two previous anti-PD1 treated cohorts 14,15 , in contrast to what has been reported in patients with melanoma treated with anti-CTLA4 16 (Extended Data Figure 3c) or patients with lung and bladder cancer treated with anti-PD-1/L1 therapy.”
InfluentialWhole-genome landscapes of major melanoma subtypes
Hayward, N. K., Wilmott, J. S., Waddell, N., Johansson, P. A., Field, M. A., Nones, K., Patch, A.-M., Kakavand, H., Alexandrov, L. B., Burke, H., et al. (2017) · Nature · doi:10.1038/nature22071 · Cited by 1,461
Self-citationMYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337 · cited 4×
“13 Our DM series had similar mutational load to NF-1 subtype cases (regardless of histological classification) in a combined series from two reports of patients with anti-PD-1 treated advanced melanoma 14,15 and in TCGA data.”
InfluentialSelf-citationPD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258 · cited 1×
“21,28 Our data suggests that DM, and probably the non-DM NF-1 subtype arising from sun-exposed areas, have a high response rate to PD-1 blockade therapy due to having a more dynamic pre-existing adaptive immune response process.”
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069
Self-citationTargeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M., Hawkins, W. G., Shapiro, I. M., Weaver, D. T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4123 · Cited by 1,060 · cited 1×
“27 However, our data challenges this notion, as there are indeed pre-existing T cell infiltrates in the invasive edge of DM lesions, and a much higher response rate to anti-PD1 therapy than any other subtypes of melanoma.”
Roh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859 · cited 2×
“13 Our DM series had similar mutational load to NF-1 subtype cases (regardless of histological classification) in a combined series from two reports of patients with anti-PD-1 treated advanced melanoma 14,15 and in TCGA data.”
InfluentialSelf-citationDaud, A. I., Wolchok, J. D., Robert, C., Hwu, W.-J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2477 · Cited by 665 · cited 1×
“14,17 We evaluated whether the presence of CD8+ T cells and PD-L1 in DM was associated with response to anti-PD1/L1 therapy 18,19 using 19 available pre-treatment DM tumour biopsies compared to 13 non-DM samples (seven with a complete or partial response, six with progressive disease) using digital…”
Self-citationAberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., Maeda, T., Nagata, Y., Kitanaka, A., Mizuno, S., et al. (2016) · Nature · doi:10.1038/nature18294 · Cited by 651 · cited 1×
“25 Therefore, the higher PD-L1 expression in DM is likely due to a reactive response to CD8 T cell infiltrates reflective of adaptive immune resistance.”
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
Krauthammer, M., Kong, Y., Bacchiocchi, A., Evans, P., Pornputtapong, N., Wu, C., McCusker, J. P., Ma, S., Cheng, E., Straub, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3361 · Cited by 402
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
Dorand, R. D., Nthale, J., Myers, J. T., Barkauskas, D. S., Avril, S., Chirieleison, S. M., Pareek, T. K., Abbott, D. W., Stearns, D. S., Letterio, J. J., et al. (2016) · Science · doi:10.1126/science.aae0477 · Cited by 315
Shain, A. H., Garrido, M., Botton, T., Talevich, E., Yeh, I., Sanborn, J. Z., Chung, J., Wang, N. J., Kakavand, H., Mann, G. J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3382 · Cited by 283
Self-citationCutaneous Desmoplastic Melanoma: Reappraisal of Morphologic Heterogeneity and Prognostic Factors
Busam, K. J., Mujumdar, U., Hummer, A. J., Nobrega, J., Hawkins, W. G., Coit, D. G., & Brady, M. S. (2004) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000141391.91677.a4 · Cited by 199
NF1 Mutations Are Common in Desmoplastic Melanoma
Wiesner, T., Kiuru, M. H., Scott, S. N., Arcila, M. E., Halpern, A. C., Hollmann, T. J., Berger, M. F., & BUSAM, K. J. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000451 · Cited by 134
Clinicopathologic Predictors of Survival in Patients with Desmoplastic Melanoma
Han, D., Han, G., Zhao, X., Rao, N. G., Messina, J. L., Marzban, S. S., Sarnaik, A. A., Cruse, C. W., Sondak, V. K., & Zager, J. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119716 · Cited by 37
Self-citationFrydenlund, N., Leone, D. A., Yang, S., Hoang, M. P., Deng, A., Hernández‐Pérez, M., Singh, R. P., Biswas, A., Yaar, R., & Mahalingam, M. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.210 · Cited by 28 · cited 1×
“20 There were no significant differences in the density of CD8+ cells in the tumour parenchyma, or CD8+ and PD-L1+ cells in the invasive margin (p = 0.12, p = 0.41, p = 0.16, Figure 3b, 3c and 3d).”
Influential
Cited by
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Self-citationApproaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Tertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
Metadata
- Authors
- Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., Gherardini, P. F., Chmielowski, B., Wang, X., Shintaku, I. P., Wei, C., Sosman, J. A., Joseph, R. W., Postow, M. A., Carlino, M. S., Hwu, W.-J., Scolyer, R. A., Messina, J., Cochran, A. J., Long, G. V., & Ribas, A.
- Affiliations
- University of California, Los Angeles (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, San Francisco (US)
- Vanderbilt University (US)
- Melanoma Institute Australia (AU)
- Memorial Sloan Kettering Cancer Center (US)
- Georgetown Lombardi Comprehensive Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Mayo Clinic (US)
- The University of Sydney (AU)
- University of South Florida (US)
- Corresponding author
- Ribas, Antoni
- ORCID
- Eroglu, Zeynep
- Zaretsky, Jesse M.
- Kim, Dae Won
- Algazi, Alain
- Johnson, Douglas B.
- Munhoz, Rodrigo
- Rapisuwon, Suthee
- Gherardini, Pier Federico
- Chmielowski, Bartosz
- Wang, Xiaoyan
- Sosman, Jeffrey A.
- Joseph, Richard W.
- Postow, Michael A.
- Carlino, Matteo S.
- Hwu, Wen-Jen
- Scolyer, Richard A.
- Messina, Jane
- Long, Georgina V.
- Ribas, Antoni
- Venue
- Nature
- Published
- 2018-01
- Volume
- 553
- Issue
- 7688
- Pages
- 347-350
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5773412
- OpenAlex
- W2784063247
- Cited by
- 338
- References
- 31
- Citations by year
- 2026: 10 · 2025: 25 · 2024: 36 · 2023: 47 · 2022: 37 · 2021: 52 · 2020: 48 · 2019: 54 · 2018: 28
- FWCI
- 17.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- Funders
- American Society of Clinical Oncology
- Moffitt Cancer Center (P30CA076292, CA076292)
- Tower Cancer Research Foundation
- Hope Foundation
- Parker Institute for Cancer Immunotherapy (R35 CA197633)
- University of Sydney
- National Institutes of Health (CA197633)
- National Health and Medical Research Council
- National Cancer Institute (CA197633, P01CA168585, CA076292, CA168585, P50CA168536, K12CA090625, P30CA008748, P30CA076292, R35CA197633)
- National Institute of General Medical Sciences (T32GM008042)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- desmoplastic melanoma, anti-PD-1 therapy, PD-L1 blockade, immune checkpoint inhibitors, immunotherapy response, CD8+ T cell infiltration, PD-L1 expression, tumor mutational burden, NF1 mutation, tumor stroma, UV-induced DNA damage, tumor-infiltrating immune cells
- MeSH terms
- Biopsy, Humans, Immunotherapy, Melanoma, Mutation, Retrospective Studies, CD8-Positive T-Lymphocytes, Neurofibromin 1, Cell Cycle Checkpoints, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.